C4′-Substituted Cannabinoid Derivative for Anticonvulsant Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid-based treatments for conditions like epilepsy and seizures, particularly generalized seizures and tonic-clonic seizures, are not sufficiently effective, necessitating the development of more potent therapeutic options.
Innovation Solution
A synthetic cannabinoid compound, (1'R,2'R)-5'-methyl-4-(1-methyl-1H-pyrazol-4-yl)-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydro-[1,1'-biphenyl]-2,6-diol, is developed, which can be administered via various routes and formulated into pharmaceutical compositions for treating conditions such as epilepsy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cannabinoid-based treatments are used, then treatment coverage is provided, but treatment effectiveness is insufficient for epilepsy and seizures
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of existing cannabinoids to create novel derivatives with enhanced pharmacological properties. Specifically, the invention introduces substitutions at the C4' position of the cannabidiol core structure, creating compounds with improved affinity for cannabinoid receptors and enhanced anticonvulsant activity compared to natural cannabinoids
Solution Approach 2:
The patent employs composite materials by combining the cannabidiol core structure with various substituent groups (such as halogen atoms, alkyl groups, or aryl groups) to create hybrid molecular structures. These composite cannabinoid derivatives integrate the beneficial properties of the parent CBD molecule with additional functional groups that enhance therapeutic effectiveness against seizures
2Reliability
If more potent cannabinoid derivatives are developed, then treatment effectiveness improves, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the modification strategy into systematic categories: substitutions at specific positions (C4'), different types of substituents (halogens, alkyl, aryl groups), and various attachment patterns. This segmented approach allows for methodical exploration of structure-activity relationships while maintaining manageable complexity through organized synthesis routes
Solution Approach 2:
The patent implements local quality by introducing substitutions specifically at the C4' position of the cannabidiol structure rather than modifying the entire molecule. This localized modification strategy enhances therapeutic activity while minimizing overall structural complexity, allowing the core pharmacophore to remain recognizable and functional
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention relates to a cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof. The cannabinoid derivative of the invention is an analogue of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the cannabinoid derivative of the invention.